ERLOTINIB
erlotinib 150 mg tablet, 30
ERLOTINIB (10014C)
10014C
Manner of administration:Oral
Restriction
Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 3 | DPMQ: $538.96 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||